DMD

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


Drug Metabolism and Disposition Fast Forward
First published on December 2, 2004; DOI: 10.1124/dmd.104.002212


0090-9556/05/3303-312-320$20.00
DMD 33:312-320, 2005

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
dmd.104.002212v1
33/3/312    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bessette, E. E.
Right arrow Articles by Kaminsky, L. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bessette, E. E.
Right arrow Articles by Kaminsky, L. S.

MECHANISMS OF ARSENITE-MEDIATED DECREASES IN BENZO[K]FLUORANTHENE-INDUCED HUMAN CYTOCHROME P4501A1 LEVELS IN HEPG2 CELLS

Erin E. Bessette, Michael J. Fasco, Brian T. Pentecost, and Laurence S. Kaminsky

New York State Department of Health, Wadsworth Center (M.J.F., B.T.P., L.S.K.), Albany, New York; and Department of Environmental Health and Toxicology, University at Albany, State University of New York (E.E.B., M.J.F., B.T.P., L.S.K.), Albany, New York

Polycyclic aromatic hydrocarbons (PAHs) and heavy metals are often environmental cocontaminants that could interact to alter PAH carcinogenicity. The heavy metal, arsenite, and the PAH, benzo[k]fluoranthene, were used as prototypes to investigate, in human HepG2 cells, mechanisms whereby the bioactivation of benzo[k]fluoranthene by human CYP1A1 could be diminished by arsenite-mediated decreases in CYP1A1 induction by benzo[k]fluoranthene. To determine whether arsenite down-regulates CYP1A1 transcription, quantitative real-time reverse transcriptase-polymerase chain reaction assays and luciferase reporter gene expression assays were used with HepG2 cells treated with benzo[k]fluoranthene and arsenite, separately and as a mixture. Benzo[k]fluoranthene (0.5 µM) and arsenite (5 µM) markedly decreased benzo[k]fluoranthene-mediated induction of CYP1A1 mRNA by 45%. Plasmids containing the CYP1A1 promoter region (pHu-1A1-FL) were induced 7.4-fold over vehicle by benzo[k]fluoranthene (0.5 µM), whereas arsenite (1, 2.5, or 5 µM) decreased reporter gene expression by 46%, 45%, and 61%, respectively. The plasmid, pHu-1A1-{Delta}100-FL, lacked xenobiotic response element (XRE) sites at –1061 and –981 and showed greater responsiveness relative to pHu-1A1-FL, by 1.7-fold. Benzo[k]fluoranthene (0.5 µM) and arsenite (1, 2.5, or 5 µM) decreased reporter gene expression by 0%, 27%, and 39%, respectively, relative to expression levels produced by benzo[k]fluoranthene alone. Arsenite is stable for at least 48 h in the HepG2 cell medium with respect to its ability to diminish CYP1A1 benzo[k]fluoranthene induction. Arsenite did not affect benzo[k]fluoranthene induction directly through XRE sites, nor did it affect the stability of CYP1A1 mRNA. Thus, arsenite affects the transcriptional regulation of the benzo[k]fluoranthene-mediated induction of CYP1A1 and could diminish PAH carcinogenicity by decreasing bioactivation by CYP1A1.


Address correspondence to: Dr. Laurence S. Kaminsky, New York State Department of Health, Wadsworth Center, PO Box 509, Albany, NY 12201-0509. E-mail: kaminsky{at}wadsworth.org




This article has been cited by other articles:


Home page
Drug Metab. Dispos.Home page
A. Anwar-Mohamed and A. O. S. El-Kadi
Down-Regulation of the Carcinogen-Metabolizing Enzyme Cytochrome P450 1a1 by Vanadium
Drug Metab. Dispos., September 1, 2008; 36(9): 1819 - 1827.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
R. Ueda, H. Iketaki, K. Nagata, S. Kimura, F. J. Gonzalez, K. Kusano, T. Yoshimura, and Y. Yamazoe
A Common Regulatory Region Functions Bidirectionally in Transcriptional Activation of the Human CYP1A1 and CYP1A2 Genes
Mol. Pharmacol., June 1, 2006; 69(6): 1924 - 1930.
[Abstract] [Full Text] [PDF]


Home page
Toxicol SciHome page
H. M. Korashy and A. O. S. El-Kadi
Regulatory Mechanisms Modulating the Expression of Cytochrome P450 1A1 Gene by Heavy Metals
Toxicol. Sci., November 1, 2005; 88(1): 39 - 51.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
S. Kann, M.-y. Huang, C. Estes, J. F. Reichard, M. A. Sartor, Y. Xia, and A. Puga
Arsenite-Induced Aryl Hydrocarbon Receptor Nuclear Translocation Results in Additive Induction of Phase I Genes and Synergistic Induction of Phase II Genes
Mol. Pharmacol., August 1, 2005; 68(2): 336 - 346.
[Abstract] [Full Text] [PDF]


Home page
Drug Metab. Dispos.Home page
T. L. Noreault, V. E. Kostrubsky, S. G. Wood, R. C. Nichols, S. C. Strom, H. W. Trask, S. A. Wrighton, R. M. Evans, J. M. Jacobs, P. R. Sinclair, et al.
ARSENITE DECREASES CYP3A4 AND RXR{alpha} IN PRIMARY HUMAN HEPATOCYTES
Drug Metab. Dispos., July 1, 2005; 33(7): 993 - 1003.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2005 by the American Society for Pharmacology and Experimental Therapeutics.